Announcement • May 23
Envoy Medical, Inc. Receives A Second Staff Notification from Nasdaq Informing the Company Is Eligible for an Additional 180 Day Period, Until November 16, 2026, to Meet the Bid Price Requirement As previously disclosed, on November 19, 2025, Envoy Medical, Inc. (the Company), received a staff determination notice (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq), informing the Company that its Class A Common Stock, par value $0.0001 per share (the Common Stock), had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market (the Capital Market) under Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement) for the 30 consecutive business days prior to the date of the Notice. The Notice had no immediate effect on the listing of the Common Stock on Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until May 18, 2026 (the Compliance Date), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Common Stock was required to meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to the Compliance Date. On May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an additional 180 day period, until November 16, 2026, to meet the Bid Price Requirement (the Second Compliance Period). Nasdaq's determination that the Company is eligible for a Second Compliance Period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for listing on the Capital Market with the exception of the bid price requirement and the Company's written notice to Nasdaq of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. Reported Earnings • May 12
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: US$0.083 loss per share (improved from US$0.29 loss in 1Q 2025). Net loss: US$5.70m (loss narrowed 8.6% from 1Q 2025). Revenue missed analyst estimates by 35%. Earnings per share (EPS) exceeded analyst estimates by 43%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 24
Full year 2025 earnings released: US$1.02 loss per share (vs US$1.49 loss in FY 2024) Full year 2025 results: US$1.02 loss per share (improved from US$1.49 loss in FY 2024). Net loss: US$23.8m (loss narrowed 15% from FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Announcement • Mar 24
Envoy Medical, Inc., Annual General Meeting, May 12, 2026 Envoy Medical, Inc., Annual General Meeting, May 12, 2026. Location: fredrikson & byron, pa, 60 south sixth street, suite 1500, mn 55402., minneapolis United States Announcement • Feb 27
Envoy Medical Regains Compliance with Nasdaq Listing Requirement Envoy Medical Inc. ("Envoy Medical" or the "Company") announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b). As previously disclosed, the Company received a notice from Nasdaq on February 25, 2025, indicating that it was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35 million. The Company subsequently implemented strategic financing initiatives and substantially strengthened its balance sheet, resulting in regaining compliance with the applicable continuing listing requirement. Announcement • Feb 14
Envoy Medical, Inc. has completed a Follow-on Equity Offering in the amount of $29.997295 million. Envoy Medical, Inc. has completed a Follow-on Equity Offering in the amount of $29.997295 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 47,946,150
Price\Range: $0.4
Discount Per Security: $0.028
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 27,053,850
Price\Range: $0.3999
Discount Per Security: $0.028
Security Name: Series A-1 Warrants
Security Type: Equity Warrant
Securities Offered: 45,000,000
Security Name: Series A-2 Warrants
Security Type: Equity Warrant
Securities Offered: 75,000,000 New Risk • Feb 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.5m). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (US$208k revenue). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$13.5m market cap). New Risk • Feb 05
New major risk - Revenue and earnings growth Earnings have declined by 11% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.5m). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (US$208k revenue). Minor Risk Market cap is less than US$100m (US$16.6m market cap). Announcement • Dec 19
Envoy Medical, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Envoy Medical, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant Price Target Changed • Dec 10
Price target decreased by 11% to US$7.00 Down from US$7.83, the current price target is provided by 1 analyst. New target price is 726% above last closing price of US$0.85. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.19 next year compared to a net loss per share of US$1.49 last year. Announcement • Nov 26
Envoy Medical, Inc. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing Rule On November 19, 2025, Envoy Medical, Inc. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 18, 2026 (the “Compliance Date”), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to the Compliance Date. If the Company is unable to regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, Nasdaq will notify the Company of its determination to delist the Common Stock, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel. The Company intends to monitor the closing bid price of the Common Stock and will, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Reported Earnings • Nov 12
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: US$0.35 loss per share. Net loss: US$7.75m (loss widened 5.5% from 3Q 2024). Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 75% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Announcement • Oct 29
Envoy Medical Receives Positive Listing Determination from Nasdaq Envoy Medical, Inc. announced that the Nasdaq Hearings Panel (the “Panel) has granted the Company’s request for continued listing on the Nasdaq Stock Market. In granting the extension, the Panel considered several key developments, including Envoy Medical’s recent equity capital raises and debt extinguishment, which combined together substantially increased the Company’s stockholders’ equity, and the FDA’s recent approval of the Company’s advancement to the final stage of the fully implanted Acclaim® cochlear implant clinical trial. The Company also noted increased investor momentum, with over 28 million shares now outstanding, and a noticeable increase in trading volume since the trial expansion announcement. The Panel granted Envoy Medical until February 23, 2026 to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2). This deadline reflects the full extent of the Panel’s discretionary authority to allow continued listing while the Company remains non-compliant. Envoy Medical will continue to provide timely updates to Nasdaq and the public regarding its compliance progress. Price Target Changed • Oct 09
Price target increased by 11% to US$7.83 Up from US$7.06, the current price target is an average from 3 analysts. New target price is 725% above last closing price of US$0.95. Stock is down 66% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.49 last year. New Risk • Oct 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$30m). Revenue is less than US$1m (US$222k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$18.5m market cap). New Risk • Sep 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$30m). Revenue is less than US$1m (US$222k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$28.2m market cap). Announcement • Sep 22
Envoy Medical, Inc. has filed a Follow-on Equity Offering in the amount of $2.500007 million. Envoy Medical, Inc. has filed a Follow-on Equity Offering in the amount of $2.500007 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 1,908,402
Price\Range: $1.31
Discount Per Security: $0.1114
Transaction Features: Registered Direct Offering Announcement • Aug 30
Envoy Medical, Inc. Receives Notice of Nasdaq Delisting On February 25, 2025, Envoy Medical, Inc. received a deficiency notification letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the market value of the Company’s listed securities did not meet the minimum of $35,000,000 (the “MVLS Requirement”) for the period of 30 consecutive business days between January 7, 2025 and February 24, 2025. The Notification Letter provided a 180 day period for the Company to become compliant with the MVLS Requirement. On August 26, 2025, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period. The determination letter informed the Company that it can request a hearing regarding Nasdaq’s determination with a Hearings Panel (the “Panel”) by September 2, 2025 to discuss how the Company believes it will regain compliance and why the Company believes the Hearing Panel should grant an extension. If the Company did not make a request to the Hearings Panel, the trading of the Company’s securities would be suspended at the opening of business on September 4, 2025. The Company submitted a hearing request to the Panel on August 29, 2025. The request itself will stay any trading suspension of the Company’s securities or the potential filing of a Form 25-NSE until after the Panel meeting is held and the Panel provides a decision. The Company is optimistic that it will be able to demonstrate to the Panel several different viable and relatively near-term pathways to regain compliance (including, in part, the recent resetting of its balance sheet with the full extinguishment of its debt), however, there can be no assurance that the Panel will grant the Company’s request for continued listing or provide a listing compliance extension. New Risk • Aug 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$16m free cash flow). Negative equity (-US$30m). Revenue is less than US$1m (US$222k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Market cap is less than US$100m (US$31.1m market cap). Reported Earnings • Aug 03
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.27 loss in 2Q 2024). Net loss: US$6.94m (loss widened 31% from 2Q 2024). Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 9.1%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Recent Insider Transactions • May 28
Independent Chairman recently bought US$82k worth of stock On the 27th of May, Charles Brynelsen bought around 50k shares on-market at roughly US$1.65 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Charles' only on-market trade for the last 12 months. Reported Earnings • May 04
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: US$0.29 loss per share (improved from US$0.39 loss in 1Q 2024). Net loss: US$6.24m (loss narrowed 18% from 1Q 2024). Revenue missed analyst estimates by 29%. Earnings per share (EPS) exceeded analyst estimates by 15%. Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Major Estimate Revision • Apr 23
Consensus revenue estimates decrease by 14%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$330.0k to US$280.0k. EPS estimate increased from -US$1.49 to -US$1.37 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at US$7.06. Share price rose 9.8% to US$1.45 over the past week. Announcement • Apr 14
Envoy Medical, Inc., Annual General Meeting, May 28, 2025 Envoy Medical, Inc., Annual General Meeting, May 28, 2025. Location: at fairfield inn & suites, 1125 county road e east, vadnais heights, minnesota 55110, United States Price Target Changed • Apr 03
Price target increased by 7.7% to US$7.00 Up from US$6.50, the current price target is an average from 4 analysts. New target price is 407% above last closing price of US$1.38. Stock is down 76% over the past year. The company is forecast to post a net loss per share of US$1.49 next year compared to a net loss per share of US$1.49 last year. Reported Earnings • Mar 31
Full year 2024 earnings released: US$1.49 loss per share (vs US$2.38 loss in FY 2023) Full year 2024 results: US$1.49 loss per share (improved from US$2.38 loss in FY 2023). Net loss: US$28.0m (loss narrowed 6.5% from FY 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Announcement • Mar 04
Envoy Medical Receives Deficiency Notification Letter from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2) On February 25, 2025, Envoy Medical, Inc. (the ‘Company’) received a deficiency notification letter (the ‘Notification Letter’) from The Nasdaq Stock Market (‘Nasdaq’) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the ‘Rule’) because the market value of the Company’s listed securities did not meet the minimum of $35,000,000 for the period for 31 consecutive business days between January 7, 2025 and February 24, 2025. Pursuant to Nasdaq’s Listing Rules, the Company will return to compliance if the market value of its listed securities exceeds $35,000,000 for ten consecutive business days during the subsequent 180 day period, which will expire on August 25, 2025. In the event the Company does not regain compliance with the Rule prior to the expiration of the compliance period, it may be subject to delisting from Nasdaq. Announcement • Feb 26
Envoy Medical, Inc. Announces the Successful Enrollment of the First Two Participants in Its Pivotal Clinical Study Envoy Medical, Inc. announced the successful enrollment of the first two participants in its pivotal clinical study. The purpose of the study is to investigate the safety and efficacy of the fully implanted Acclaim cochlear implant and support its eventual premarket approval (PMA) application. If successful, the fully implanted Acclaim cochlear implant could represent a paradigm shift in the cochlear implant industry and provide a significant business opportunity for Envoy Medical. Both study participants were implanted at Ear and Hearing | Center for Neurosciences in Tucson, Arizona by Dr. Abraham Jacob. In addition to the Ear and Hearing | Center for Neurosciences in Tucson, Arizona, six other investigational sites were selected to be part of the study. A full list of investigational sites and additional information on the Acclaim pivotal clinical study can be found HERE. The fully implanted Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and was first implanted in three participants during an early feasibility study (EFS) at Mayo Clinic in Rochester, Minnesota in 2022. They believe the fully implanted Acclaim Cochlear Implant ('Acclaim CI') is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. New Risk • Dec 05
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Negative equity (-US$19m). Earnings are forecast to decline by an average of 3.9% per year for the foreseeable future. Revenue is less than US$1m (US$278k revenue). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$26m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (US$42.5m market cap). Price Target Changed • Nov 20
Price target decreased by 10% to US$6.44 Down from US$7.19, the current price target is an average from 4 analysts. New target price is 216% above last closing price of US$2.04. Stock is up 96% over the past year. The company is forecast to post a net loss per share of US$1.30 next year compared to a net loss per share of US$2.38 last year. New Risk • Nov 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$27m free cash flow). Negative equity (-US$19m). Revenue is less than US$1m (US$278k revenue). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$25m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (US$43.3m market cap). Reported Earnings • Nov 17
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: US$0.37 loss per share (down from US$0.13 profit in 3Q 2023). Net loss: US$7.34m (down US$8.70m from profit in 3Q 2023). Revenue missed analyst estimates by 25%. Earnings per share (EPS) also missed analyst estimates by 45%. Revenue is forecast to grow 75% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Announcement • Nov 01
Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device Envoy Medical, Inc. announced that its Investigational Device Exemption (IDE) application for its pivotal study of the Acclaim Fully Implanted Cochlear Implant has been approved by the U.S. Food and Drug Administration (FDA). The Acclaim technology includes an implanted sensor designed to leverage the natural anatomy of the ear to capture sound, making it different from existing cochlear implants on the market. The Company plans to select some of the top cochlear implant institutions in the U.S. as investigational sites for the study. As IRB approvals are obtained, the Company will share information on the investigational sites for interested patients. The FDA approved the IDE application as a staged clinical study. This allows preliminary clinical data to be gathered on a subset of patients prior to expanding enrollment to the full subject cohort. As with any investigational device, approval of an IDE application does not ensure that the results of the investigation will provide a reasonable assurance of the safety and effectiveness or assure a determination of approval for a premarket submission. Fully Implanted Acclaim Cochlear Implant: The fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. The Esteem FI-AMEI hearing implant offers true 24/7 hearing. Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use. Price Target Changed • Oct 14
Price target increased by 11% to US$7.19 Up from US$6.50, the current price target is an average from 4 analysts. New target price is 195% above last closing price of US$2.44. Stock is up 8.4% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$2.38 last year. New Risk • Oct 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$22m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$12m). Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Revenue is less than US$1m (US$302k revenue). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$22m net loss next year). Market cap is less than US$100m (US$63.7m market cap). Announcement • Sep 10
Envoy Medical, Inc., Annual General Meeting, Nov 14, 2024 Envoy Medical, Inc., Annual General Meeting, Nov 14, 2024. Location: at delta hotels minneapolis northeast, 1330 industrial blvd ne, minnesota., minneapolis United States Reported Earnings • Aug 13
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.27 loss per share. Net loss: US$5.31m (loss narrowed 58% from 2Q 2023). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 3.8%. Revenue is forecast to grow 6.9% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Announcement • Jun 13
Envoy Medical, Inc. Announces Board Changes Envoy Medical, Inc. announced on June 6, 2024, Dr. Whitney Haring-Smith, notified the company of his decision to resign from the board of directors of the company effective immediately. Dr. Haring-Smith did not resign from the board because of a disagreement with the company on any matter relating to the company's operations, policies or practices. On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith's resignation. Mr. Crowe has decades of experience in the medical device industry with a focus on operations. Since March 2023, Mr. Crowe has served as Senior Vice President Operations for Bioventus LLC. Previously, he served as Vice President Operations for Abbott Vascular from January 2015 to March 2023. Mr. Crowe earlier served in similar roles for Caris Life Sciences, Covidien Devices, Johnson & Johnson, Iomega Corporation, and SKF USA, Inc. Mr. Crowe earned a bachelor's degree in engineering from the University of Louisville and an MBA from Duke University. Reported Earnings • May 17
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.099 loss in 1Q 2023) First quarter 2024 results: US$0.32 loss per share. Net loss: US$6.27m (loss narrowed 54% from 1Q 2023). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Reported Earnings • Apr 07
Full year 2023 earnings released: US$2.38 loss per share (vs US$1.57 loss in FY 2022) Full year 2023 results: US$2.38 loss per share (further deteriorated from US$1.57 loss in FY 2022). Net loss: US$29.9m (loss widened 88% from FY 2022). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. New Risk • Apr 03
New major risk - Revenue and earnings growth Revenue has declined by 5.6% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average weekly change). Revenue has declined by 5.6% over the past year. Revenue is less than US$1m (US$241k revenue). Minor Risk Market cap is less than US$100m (US$87.6m market cap). Board Change • Feb 14
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Independent Director Mona Patel is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Nov 16
Envoy Medical, Inc. announced delayed 10-Q filing On 11/14/2023, Envoy Medical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Oct 20
Envoy Medical, Inc. Announces New Clinical Publication Reports First Three Patients in Early Feasibility Trial for Envoy Medical’s Fully Implanted Cochlear Device A recent clinical publication in the Journal of Clinical Medicine (JCM) highlighted early surgical experience with Envoy Medical, Inc.’s (“Envoy Medical”) investigational Acclaim® fully implantable cochlear implant. According to the publication, "All three surgeries proceeded without complication, and at activation, all three patients were hearing through their devices. Surgery is more technically challenging compared to a standard cochlear implant, but the skills needed can be mastered by a dedicated otologic surgeon." The Company currently expects to file for an investigational device exemption (IDE) in early 2024 to commence a pivotal clinical trial later that year. Current cochlear implants rely on bulky external hardware that are held in place on the head by a magnet, which can cause discomfort and may not be suitable for all activities, including sleeping, showering, swimming, strenuous activity and other common daily events. Envoy Medical’s device, the fully implanted Acclaim® cochlear implant seeks to alleviate these limitations by being the first fully implanted cochlear implant (sometimes referred to as a totally implanted cochlear implant or “TICI”). By using an implanted middle ear sensor and an implanted rechargeable power supply, Acclaim® aims to eliminate the need for any externally worn components. Acclaim was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and is currently in an early feasibility study at Mayo Clinic (Rochester, Minnesota). Envoy Medical’s Acclaim® may become the first fully implanted cochlear implant to begin a pivotal trial in the United States. Unlike other cochlear implants, Acclaim® intends to leverage the patient’s natural ear – rather than an external microphone – to capture acoustic energy. The Acclaim® is designed to not require the use of an external processor during the day or daily recharging. The Mayo Clinic authors note: “While it is only conjecture at this point, one may presume that increased breadth and comfort of use may improve quality-of-life for many recipients, particularly those who feel their disability prevents them from taking part in certain activities.” The authors also highlight that this novel device is still developing. Certain patients may not be good candidates and that programming requires careful monitoring. If approved by the FDA, Envoy Medical intends to target a significantly under-penetrated adult cochlear implant market, which it believes to be more than $80 billion in the US. The paper notes that the success of cochlear implants has resulted in steadily widening the criteria by which patients can qualify for a cochlear device. Board Change • Oct 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Paul Waldon was the last director to join the board, commencing their role in 2011. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.